文献速递眼底病与葡萄膜炎青光眼

玻璃体内地塞米松(Ozurdex)缓释植入剂注射后高眼压

OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT.
PubMed 文献 · Retina · 2017-01-01

该回顾性连续病例系列纳入某三级学术中心接受一次或多次玻璃体内Ozurdex植入的52例患者(59眼),共94次注射。高眼压定义为单次测量≥30 mmHg或较基线升高≥10 mmHg,14例(26.9%)发生高眼压,13次注射(13.8%)后启用青光眼滴眼液,3例(3.2%)需青光眼侵入性手术且均有青光眼或疑似青光眼。

要点

  • 接受Ozurdex注射的患者中26.9%发生高眼压。
  • 13次注射(13.8%)后开始使用青光眼滴眼液。
  • 3例(3.2%)需青光眼侵入性手术,均有青光眼或疑似青光眼。

核心结论

  • 接受Ozurdex注射的患者中26.9%发生高眼压。
  • 所有需青光眼侵入性手术的患者均存在青光眼或疑似青光眼因素。
  • 接受多次注射的患者中眼压升高的比例更高,但相对眼压升高无显著差异。

研究设计与样本

  • 回顾性连续病例系列,纳入某三级学术中心接受一次或多次玻璃体内Ozurdex植入的患者。

主要发现

  • 共回顾52例患者(59眼)的94次注射,其中40眼接受单次注射,19眼接受多次注射。
  • 14例(26.9%)发生高眼压;13例(25%)有青光眼或疑似青光眼,其中6例发生高眼压。
  • 13次注射(13.8%)后启用青光眼滴眼液;3例(3.2%)需青光眼侵入性手术,均有青光眼或疑似青光眼(其中1例与新生血管性青光眼相关,不太可能与Ozurdex后激素反应相关)。
  • 单次与多次Ozurdex注射间相对眼压升高(即最终随访或后续玻璃体内注射时与基线的差值)无差异(P=0.883)。

关键数值与推荐

  • 高眼压定义为单次测量≥30 mmHg或较基线升高≥10 mmHg。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate ocular hypertension (OHT) after Ozurdex injection to determine the incidence of OHT, therapy for OHT, and any associative factors such as diagnosis, underlying glaucoma and therapy, or sequential Ozurdex injection(s). METHODS: Retrospective consecutive case series with patients receiving one or more intravitreal Ozurdex implantations at a tertiary care academic center. Ocular hypertension was defined as a single measurement of ≥30 mmHg or an increase of ≥10 mmHg from baseline. RESULTS: Ninety-four injections in 52 patients (59 eyes) were reviewed. Forty eyes received a single injection, and 19 eyes received multiple injections. Ocular hypertension developed in 14 patients (26.9%). Thirteen patients (25%) had preexisting glaucoma or suspicion of glaucoma, and 6 of these developed OHT. Glaucoma eye drops were initiated after 13 injections (13.8%). Invasive surgery for glaucoma was required in 3 patients (3.2%): all had glaucoma or suspicion of glaucoma (one case was related to neovascular glaucoma and unlikely related to steroid response after Ozurdex). There was no difference in relative intraocular pressure increase (i.e., difference between final follow-up or subsequent intravitreal injection vs. baseline) between single versus multiple Ozurdex injections (P = 0.883). CONCLUSION: Patients (26.9%) who received Ozurdex developed OHT. Glaucoma or glaucoma-suspicion factors were present in all patients who required invasive surgery for glaucoma. A greater proportion of patients who received multiple injections had an intraocular pressure elevation, but the relative intraocular pressure increase was not significant.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Chin EK, Almeida DRP, Velez G, et al. OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT. Retina. 2017. PMID: 27806001. doi:10.1097/IAE.0000000000001364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。